Missed NVDA?
Don’t Miss the Next One.
Join 5,000+ investors using Ticker Nerd’s Market Radar to stay ahead of major market moves, analyst upgrades, and trending opportunities — for free.
NUTX Stock Forecast 2025-2026
$114.65
Current Price
$643.41M
Market Cap
Buy 3
Hold 0
Sell 0
Wall St Analyst Ratings
Distance to NUTX Price Targets
+161.7%
To High Target of $300.00
+91.9%
To Median Target of $220.00
+78.8%
To Low Target of $205.00
NUTX Price Momentum
-6.8%
1 Week Change
+10.6%
1 Month Change
+263.3%
1 Year Change
+261.8%
Year-to-Date Change
-37.8%
From 52W High of $184.27
+343.3%
From 52W Low of $25.86
📊 TOP ANALYST CALLS
Did NUTX Make This Month's Elite Buy List?
We don't follow just any analyst — only the top 3% with a proven track record make our cut. See if Nutex Health is one of their latest high-conviction picks.
Latest NUTX Stock Price Targets & Analyst Predictions
Based on our analysis of 3 Wall Street analysts, NUTX has a bullish consensus with a median price target of $220.00 (ranging from $205.00 to $300.00). The overall analyst rating is N/A (N/A/10). Currently trading at $114.65, the median forecast implies a 91.9% upside. This outlook is supported by 3 Buy, 0 Hold, and 0 Sell ratings.
The most optimistic forecast comes from Bill Sutherland at Benchmark, projecting a 161.7% upside. Conversely, the most conservative target is provided by Anthony Vendetti at Maxim Group, suggesting a 78.8% upside.
Please note that analyst price targets are forward-looking estimates subject to substantial market, economic, and company-specific risks. Past performance does not guarantee future results, and actual stock performance may materially differ from these projections. Investors should conduct their own due diligence and consider their investment objectives and risk tolerance before making investment decisions.
NUTX Analyst Ratings
3
Buy
0
Hold
0
Sell
NUTX Price Target Range
Low
$205.00
Average
$220.00
High
$300.00
Current: $114.65
Latest NUTX Stock Forecasts by Analyst
These are the latest 20 analyst ratings and price targets for NUTX.
| Date | Firm | Analyst | Rating | Change | Price Target |
|---|---|---|---|---|---|
| Aug 26, 2025 | Maxim Group | Anthony Vendetti | Buy | Maintains | $205.00 |
| Jul 10, 2025 | Benchmark | Buy | Reiterates | $N/A | |
| May 20, 2025 | Maxim Group | Anthony Vendetti | Buy | Maintains | $225.00 |
| May 15, 2025 | Benchmark | Bill Sutherland | Buy | Maintains | $300.00 |
| Apr 9, 2025 | Benchmark | Buy | Maintains | $N/A | |
| Apr 8, 2025 | Maxim Group | Anthony Vendetti | Buy | Maintains | $100.00 |
| Feb 13, 2025 | Maxim Group | Anthony Vendetti | Buy | Maintains | $75.00 |
| Nov 12, 2024 | Benchmark | Bill Sutherland | Buy | Maintains | $60.00 |
| Nov 12, 2024 | Maxim Group | Anthony Vendetti | Buy | Maintains | $50.00 |
| Sep 18, 2024 | Maxim Group | Anthony Vendetti | Buy | Initiates | $45.00 |
| Aug 21, 2024 | Benchmark | Bill Sutherland | Buy | Maintains | $45.00 |
| Jan 25, 2024 | Benchmark | Bill Sutherland | Buy | Maintains | $1.00 |
| Nov 14, 2023 | Benchmark | Bill Sutherland | Buy | Maintains | $1.50 |
| Aug 29, 2023 | Benchmark | Bill Sutherland | Buy | Reiterates | $2.50 |
| May 17, 2023 | Benchmark | Bill Sutherland | Buy | Maintains | $2.50 |
| Mar 9, 2023 | Benchmark | Bill Sutherland | Buy | Reiterates | $3.00 |
| Dec 23, 2022 | Benchmark | Bill Sutherland | Buy | Initiates | $3.00 |
Nutex Health Inc. (NUTX) Competitors
The following stocks are similar to Nutex Health based on their market capitalization and industry sector. These similar stocks potentially provide investors with alternative investment opportunities within the same market segment.
Nutex Health Inc. (NUTX) Financial Data
Nutex Health Inc. has a market capitalization of $643.41M with a P/E ratio of 2.4x. The company generates $624.28M in trailing twelve-month revenue with a 10.8% profit margin.
Revenue growth is +214.0% quarter-over-quarter, while maintaining an operating margin of +34.1% and return on equity of +78.9%.
Valuation Metrics
Market Cap
$643.41M
Enterprise Value
$1.07B
P/E Ratio
2.4x
PEG Ratio
0.0x
Price/Sales
1.1x
Growth & Margins
Revenue Growth (YoY)
+214.0%
Gross Margin
N/A
Operating Margin
+34.1%
Net Margin
+10.8%
EPS Growth
N/A
Financial Health
Cash/Price Ratio
+13.3%
Current Ratio
2.3x
Debt/Equity
124.2x
ROE
+78.9%
ROA
+22.3%
💡 SKIP THE NOISE
97% of Analyst Ratings Go Nowhere
We filter thousands of calls to find the few that actually matter. Get the top analyst buy ratings — tracked and updated every Monday and Thursday.
Nutex Health Inc. (NUTX) Business Model
About Nutex Health Inc.
What They Do
Provides efficient healthcare services through micro-hospitals.
Business Model
Nutex Health Inc. operates a network of micro-hospitals and freestanding emergency rooms, generating revenue by providing emergency care and other medical services to communities, particularly in underserved areas. The company focuses on patient-centered care and innovative delivery models to enhance patient outcomes.
Additional Information
The company's scalable and adaptable infrastructure addresses the increasing demand for emergency medical care. Nutex Health collaborates with healthcare professionals and stakeholders to improve the effectiveness of medical services, thus positively impacting the healthcare landscape.
Company Information
Sector
Healthcare
Industry
Medical Care Facilities
Employees
830
CEO
Dr. Thomas T. Vo M.B.A., M.D.
Country
United States
IPO Year
2013
Website
www.nutexhealth.comNutex Health Inc. (NUTX) Latest News & Analysis
Latest News
Quick Summary
Nutex is accused of concealing HaloMD's insurance fraud, misrepresenting internal controls and stock compensation, and overstating its business and financial outlook.
Why It Matters
Allegations of fraud and misstatements can lead to regulatory scrutiny, legal liabilities, and loss of investor trust, negatively impacting Nutex's stock value and long-term viability.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Nutex Health Inc. (NASDAQ: NUTX) faces a class-action lawsuit for allegedly using deceptive billing practices to inflate financial results, leading to investor losses.
Why It Matters
The lawsuit against Nutex Health raises concerns about its financial integrity and operational practices, potentially impacting stock value and investor confidence. Legal issues may lead to further losses.
Source: PRNewsWire
Market Sentiment:
Neutral
Quick Summary
Rosen Law Firm alerts Nutex Health Inc. (NASDAQ: NUTX) investors of a lead plaintiff deadline on October 21, 2025, for securities purchased between August 8, 2024, and August 14, 2025.
Why It Matters
The October 21, 2025 deadline for lead plaintiffs in the Nutex Health Inc. securities case indicates potential legal liabilities, impacting investor sentiment and stock performance.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Bragar Eagel & Squire urges Nutex (NUTX) investors who lost money between August 8, 2024, and August 14, 2025, to contact them to discuss legal options at (212) 355-4648.
Why It Matters
Legal action regarding Nutex may indicate potential issues with the company, affecting stock value and investor confidence. Investors could face losses or seek compensation.
Source: GlobeNewsWire
Market Sentiment:
Neutral
Quick Summary
Levi & Korsinsky, LLP has initiated a class action lawsuit for Nutex Health Inc. (NASDAQ: NUTX) investors, targeting alleged securities fraud from August 8, 2024, to August 14, 2025.
Why It Matters
The class action lawsuit against Nutex Health Inc. indicates potential legal and financial risks, which may impact stock performance and investor confidence.
Source: PRNewsWire
Market Sentiment:
Neutral
Source: Business Wire
Market Sentiment:
Neutral
Frequently Asked Questions About NUTX Stock
What is Nutex Health Inc.'s (NUTX) stock forecast for 2026?
Based on our analysis of 3 Wall Street analysts, Nutex Health Inc. (NUTX) has a median price target of $220.00. The highest price target is $300.00 and the lowest is $205.00.
Is NUTX stock a good investment in 2026?
According to current analyst ratings, NUTX has 3 Buy ratings, 0 Hold ratings, and 0 Sell ratings. The stock is currently trading at $114.65. Always conduct your own research and consider your investment goals before making investment decisions.
What is the long-term price prediction for NUTX stock?
Wall Street analysts predict NUTX stock could reach $220.00 in the next 12 months. This represents a 91.9% increase from the current price of $114.65. Please note that this is a projection by Wall Street analysts and not a guarantee.
What is Nutex Health Inc.'s business model?
Nutex Health Inc. operates a network of micro-hospitals and freestanding emergency rooms, generating revenue by providing emergency care and other medical services to communities, particularly in underserved areas. The company focuses on patient-centered care and innovative delivery models to enhance patient outcomes.
What is the highest forecasted price for NUTX Nutex Health Inc.?
The highest price target for NUTX is $300.00 from Bill Sutherland at Benchmark, which represents a 161.7% increase from the current price of $114.65.
What is the lowest forecasted price for NUTX Nutex Health Inc.?
The lowest price target for NUTX is $205.00 from Anthony Vendetti at Maxim Group, which represents a 78.8% increase from the current price of $114.65.
What is the overall NUTX consensus from analysts for Nutex Health Inc.?
The overall analyst consensus for NUTX is bullish. Out of 3 Wall Street analysts, 3 rate it as Buy, 0 as Hold, and 0 as Sell, with a median price target of $220.00.
How accurate are NUTX stock price projections?
Stock price projections, including those for Nutex Health Inc., are based on various factors including financial models, market conditions, and analyst forecasts. While these predictions provide valuable insights, they should be considered alongside your own research and risk tolerance.
Important Disclaimer
The information provided by Ticker Nerd is for educational and informational purposes only. It should not be considered financial or investment advice. Past performance is not indicative of future results. Always conduct your own research and consult with a qualified financial advisor before making any investment decisions. Analyst ratings and price forecasts are sourced from Wall St analysts and other experts. These projections are speculative and do not guarantee future stock performance.
Last updated: November 9, 2025 6:10 AM UTC